Information Provided By:
Fly News Breaks for February 18, 2020
Feb 18, 2020 | 07:36 EDT
Barclays analyst Gena Wang downgraded Seattle Genetics to Equal Weight from Overweight with an unchanged price target of $124. The analyst continues to like Seattle Genetics' ADC technology platform and remains optimistic about the commercial opportunities for Padcev and tucatinib. However, she sees a balanced risk/reward profile at current share levels.